Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), CEACAM6 inhibitors(Carcinoembryonic antigen related cell adhesion molecule 6 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20N2O5 |
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N |
CAS Registry86639-52-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Preclinical | US | 04 Jan 2024 |